Citation Report
List of articles citing

The discovery of novel, potent and selective PDE5 inhibitors

DOI: 10.1016/s0960-894x(01)00466-8
Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2461-4

#	Paper	IF	Citations
30	Chapter 6. Phosphodiesterase 5 inhibitors. *Annual Reports in Medicinal Chemistry*, **2002**, 37, 53-64	1.6	12
29	Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 3149-52	2.9	27
28	Phosphodiesterase 5 inhibitors: current status and potential applications. *Nature Reviews Drug Discovery*, **2002**, 1, 674-82	64.1	229
27	Phosphodiesterase-5 inhibitors for male erectile dysfunction. *Expert Opinion on Therapeutic Patents* , **2003**, 13, 1373-1388	6.8	11
26	Phosphodiesterase type 5 (PDE5) inhibitors. *Progress in Medicinal Chemistry*, **2003**, 41, 249-306	7.3	23
25	SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 1291-4	2.9	23
24	Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 1577-80	2.9	44
23	Assays for Cyclic Nucleotide-Specific Phosphodiesterases (Families 1 to 5). *Current Protocols in Pharmacology*, **2005**, 28, 3.12.1	4.1	
22	Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 2790-4	2.9	33
21	Pyrido[2,3-d]pyrimidine-2,7-dithiol in heterocyclic synthesis: Synthesis and characterization of several new fused pyridopyrimidine heterocycles. *Journal of Sulfur Chemistry*, **2005**, 26, 381-391	2.3	13
20	Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6. *Medicinal Research Reviews*, **2006**, 26, 369-95	14.4	31
19	Phosphodiesterase 5 inhibitors--drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. *Current Pharmaceutical Design*, **2006**, 12, 3459-65	3.3	50
18	Assays for cyclic nucleotide-specific phosphodiesterases (PDEs) in the central nervous system (PDE1, PDE2, PDE4, and PDE10). *Current Protocols in Neuroscience*, **2007**, Chapter 7, Unit 7.21	2.7	4
17	Cardiovascular Activity. **2007**, 47-391		
16	Phosphodiesterases. **2007**, 919-957		4
15	Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 6279-82	2.9	24
14	Bicyclic 5-6 Systems: Other Four Heteroatoms 2:2. **2008**, 599-659		4

13	A new therapeutic approach in Parkinson\'s disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 6796-802	3.4	53
12	Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction. **2010**, 135-172		
11	ChemInform Abstract: The Discovery of Novel, Potent and Selective PDE5 Inhibitors.. *ChemInform*, **2010**, 32, no-no		
10	PDE5 inhibitors and their applications. *Current Medicinal Chemistry*, **2010**, 17, 2564-87	4.3	21
9	Synthetic utility of a heterocyclic o-aminoaldehyde: synthesis of pyrazolopyridopyrimidines, pyrazolonaphthyridines, and pyrazolopyrimidonaphthyridinones. *Monatshefte F□ Chemie*, **2011**, 142, 169-175	1.4	4
8	Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 398-404	2.9	79
7	Multi-component one-pot synthesis and antimicrobial activities of 3-methyl-1,4-diphenyl-7-thioxo-4,6,8,9-tetrahydro-pyrazolo[5,4-b]pyrimidino[5,4-e]pyridine-5-one and related derivatives. *Molecules*, **2012**, 17, 14464-83	4.8	32
6	A Versatile Synthesis, PM3-Semiempirical, Antibacterial, and Antitumor Evaluation of Some Bioactive Pyrazoles. *Journal of Heterocyclic Chemistry*, **2012**, 49, 543-554	1.9	19
5	Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2017**, 32, 311-330	5.6	20
4	In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors. *Journal of Biomolecular Structure and Dynamics*, **2017**, 35, 2830-2852	3.6	1
3	Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2. *Carcinogenesis*, **2020**, 41, 1421-1431	4.6	3
2	Phosphodiesterases and the Effects of Forskolin. **2015**, 1-22		
1	Phosphodiesterases and the Effects of Forskolin. **2016**, 645-663		